BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...financing, which also saw participation from Deerfield and existing investors including Goldman Sachs, Breyer Capital and Healthcare Venture Partners...
BioCentury | Dec 24, 2019
Financial News

Dec. 27 Financial Quick Takes: Cirius, Axsome, Abeona, Monopar, Paige.AI, Freeline

...B Paige.AI Inc. raised $45 million on Dec. 18 in a series B led by Healthcare Venture Partners...
BioCentury | Sep 12, 2011
Emerging Company Profile

Tensha: Epigenetic BET

Tensha Therapeutics Inc. believes its bromodomain inhibitors are among the first compounds to directly target the MYC oncogene . The company is focusing on cancer indications while eyeing additional opportunities in inflammatory disease. Tensha was founded...
BioCentury | Feb 13, 2006
Finance

Ebb & Flow

...MPM (27.6% prior to the IPO); TL Ventures (12.1%); InterWest (11.2%); Frazier (10.7%); Thomas Weisel Healthcare Venture Partners...
Items per page:
1 - 4 of 4
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...financing, which also saw participation from Deerfield and existing investors including Goldman Sachs, Breyer Capital and Healthcare Venture Partners...
BioCentury | Dec 24, 2019
Financial News

Dec. 27 Financial Quick Takes: Cirius, Axsome, Abeona, Monopar, Paige.AI, Freeline

...B Paige.AI Inc. raised $45 million on Dec. 18 in a series B led by Healthcare Venture Partners...
BioCentury | Sep 12, 2011
Emerging Company Profile

Tensha: Epigenetic BET

Tensha Therapeutics Inc. believes its bromodomain inhibitors are among the first compounds to directly target the MYC oncogene . The company is focusing on cancer indications while eyeing additional opportunities in inflammatory disease. Tensha was founded...
BioCentury | Feb 13, 2006
Finance

Ebb & Flow

...MPM (27.6% prior to the IPO); TL Ventures (12.1%); InterWest (11.2%); Frazier (10.7%); Thomas Weisel Healthcare Venture Partners...
Items per page:
1 - 4 of 4